Growing export sales a boon for Duopharma

PETALING JAYA: Duopharma Biotech Bhd’s future earnings will still be underpinned by robust drug product purchase list or APPL for the government as well as potential synergies generated by investee companies, say analysts.

Additionally, it is foreseen that Duopharma’s bottom line may face pressures from the strengthening of the US dollar and rising electricity tariffs.